Male breast cancer: A comparison between BRCA mutation carriers and non-carriers in Hong Kong, Southern China

被引：0
|
作者：
Kwong, A.
Chau, W. W.
Wong, C. H. N.
Law, F. B. F.
Ng, E. K. O.
Suen, D. T. K.
Kurian, A. W.
West, D. W.
Ford, J. M.
Ma, E. S. K.
机构：
[1] Univ Hong Kong, Pokfulam, Hong Kong, Peoples R China
[2] Hong Kong Hereditary Breast Canc Family Registry, Happy Valley, Hong Kong, Peoples R China
[3] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[4] Hong Kong Sanitorium & Hosp, Happy Valley, Hong Kong, Peoples R China
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-123-11-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-11-02
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Contralateral Breast Cancer and Ipsilateral Breast Tumor Recurrence in BRCA1/2 Carriers and Non-Carriers at High-Risk of Hereditary Breast Cancer
    Yoon, Kyung-Hwak
    Chae, Sumin
    Kang, Eunyoung
    Shin, Hee-Chul
    Kim, Jee Hyun
    Kim, In Ah
    Park, So Yeon
    Kim, Sung-Won
    Kim, Eun-Kyu
    JOURNAL OF BREAST CANCER, 2019, 22 (04) : 587 - 598
  • [22] Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers
    Paluch-Shimon, Shani
    Friedman, Eitan
    Berger, Raanan
    Papa, Moshe
    Dadiani, Maya
    Friedman, Neil
    Shabtai, Moshe
    Zippel, Dov
    Gutman, Mordechai
    Golan, Talia
    Yosepovich, Ady
    Catane, Raphael
    Modiano, Tami
    Kaufman, Bella
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 157 (01) : 157 - 165
  • [23] Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
    Bernholtz, Shiri
    Laitman, Yael
    Kaufman, Bella
    Shimon-Paluch, Shnai
    Friedman, Eitan
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (02) : 669 - 673
  • [24] The spectrum of BRCA1 and BRCA2 mutations and clinicopathologic characteristics of young-onset breast cancer in BRCA-carriers and non-carriers
    Chen, Lili
    Fu, Fangmeng
    Lv, Jinxing
    Wang, Chuan
    CANCER RESEARCH, 2020, 80 (04)
  • [25] Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers
    Shani Paluch-Shimon
    Eitan Friedman
    Raanan Berger
    Moshe Papa
    Maya Dadiani
    Neil Friedman
    Moshe Shabtai
    Dov Zippel
    Mordechai Gutman
    Talia Golan
    Ady Yosepovich
    Raphael Catane
    Tami Modiano
    Bella Kaufman
    Breast Cancer Research and Treatment, 2016, 157 : 157 - 165
  • [26] Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers?
    Jakubowska, Anna
    Jaworska, Katarzyna
    Cybulski, Cezary
    Janicka, Anna
    Szymanska-Pasternak, Jolanta
    Lener, Marcin
    Narod, Steven A.
    Lubinski, Jan
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (05) : 837 - 842
  • [27] Breast cancer in BRCA mutation carriers: medical treatment
    Milani, Andrea
    Geuna, Elena
    Zucchini, Giorgia
    Aversa, Caterina
    Martinello, Rossella
    Montemurro, Filippo
    MINERVA GINECOLOGICA, 2016, 68 (05): : 557 - 565
  • [28] Costs of breast cancer surveillance in BRCA mutation carriers
    Kamm, Y. J. L.
    Boetes, C.
    Adang, E. M. M.
    Bult, P.
    Bonenkamp, H. J.
    Hoogerbrugge, N.
    EJC SUPPLEMENTS, 2008, 6 (07): : 94 - 95
  • [29] Comparison of Long-Term Oncological Results in Young Women with Breast Cancer between BRCA-Mutation Carriers Versus Non-Carriers: How Tumor and Genetic Risk Factors Influence the Clinical Prognosis
    Tinterri, Corrado
    Grimaldi, Simone Di Maria
    Sagona, Andrea
    Barbieri, Erika
    Darwish, Shadya
    Bottini, Alberto
    Canavese, Giuseppe
    Gentile, Damiano
    CANCERS, 2023, 15 (16)
  • [30] A comparison between Chek 2 mutation carriers and non carriers in early breast cancer patients: A clinicopathological analysis
    Huszno, J.
    Budryk, M.
    Tecza, K.
    Pilat, J. Pamula
    Grzybowska, E.
    Kolosza, Z.
    Nowara, E.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S44 - S44
12345